Sweden, Stockholm-based Pixelgen Technologies, specializing in spatial proteomics for single cells, successfully raised approximately $7.3M in a Series A funding round. The funding was spearheaded by Industrifonden and Navigare Ventures. The capital infusion is earmarked to facilitate the commercial expansion of their recently launched spatial proteomics tool. This tool analyzes cell surface proteins on single cells, promising to revolutionize drug discovery and basic science, thus driving advancements in medicine and diagnostics. With CEO Simon Fredriksson at the helm, Pixelgen Technologies has developed Molecular Pixelation, a DNA-based visualization technology platform enabling a deeper understanding of cellular activity for the development of improved medical solutions. Patrik Sobocki, Ph.D., Senior Investment Director at Industrifonden, will join Pixelgen's board of directors, contributing extensive expertise in healthcare, technology, and entrepreneurship. His addition aligns with the company's vision to further enhance research and development in the pharmaceutical sector.